Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Menin and p53 have non-synergistic effects on tumorigenesis in mice

Authors: Kelly A Loffler, Arne W Mould, Paul M Waring, Nicholas K Hayward, Graham F Kay

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

While it is now more than a decade since the first description of the gene mutation underlying the tumour predisposition syndrome multiple endocrine neoplasia type 1 (MEN1), the mechanism by which its protein product menin acts to prevent development of tumours is still poorly understood.

Methods

We undertook a genetic experiment to assess whether menin synergises with p53. Mice carrying various combinations of Men1 and Trp53 mutations were generated then survival and pathology assessed.

Results

While homozygous loss of Trp53 in mice resulted in early onset, aggressive tumours and profoundly reduced lifespan, heterozygous loss of either Trp53 or Men1 caused later onset disease, with a spectrum of tumours characteristic of each tumour suppressor gene. Loss of one copy of Men1 in animals also lacking both alleles of Trp53 did not exacerbate phenotype, based on survival, animal weight or sites of pathology, compared to Trp53 deletion alone. Dual heterozygous deletion of Men1 and Trp53 resulted in a small reduction in lifespan compared to the individual mutations, without new tumour sites. In the adrenal, we observed development of cortical tumours in dual heterozygous animals, as we have previously seen in Men1 +/− animals, and there was loss of heterozygosity at the Men1 allele in these tumours. Median number of pathology observations per animal was increased in dual heterozygous animals compared with heterozygous loss of Trp53 alone.

Conclusions

Simultaneous heterozygous deletion of Men1 in animals with either heterozygous or homozygous deletion of Trp53 did not result in formation of tumours at any new sites, implying additive rather than synergistic effects of these pathways. Mice that were Men1 +/− in addition to Trp53 +/− had tumours in endocrine as well as other sites, implying that increase in total tumour burden, at sites typically associated with either Men1 or Trp53 loss, contributed to the slight decrease in survival in Men1 +/−: Trp53 +/− animals in comparison with their littermates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997, 276: 404-407. 10.1126/science.276.5311.404.CrossRefPubMed Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997, 276: 404-407. 10.1126/science.276.5311.404.CrossRefPubMed
2.
go back to reference Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, et al: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet. 1997, 6: 1177-1183. 10.1093/hmg/6.7.1177.CrossRefPubMed Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, et al: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet. 1997, 6: 1177-1183. 10.1093/hmg/6.7.1177.CrossRefPubMed
3.
go back to reference Poisson A, Zablewska B, Gaudray P: Menin interacting proteins as clues towards the understanding of multiple endocrine neoplasia type 1. Cancer Lett. 2003, 189: 1-10. 10.1016/S0304-3835(02)00509-8.CrossRefPubMed Poisson A, Zablewska B, Gaudray P: Menin interacting proteins as clues towards the understanding of multiple endocrine neoplasia type 1. Cancer Lett. 2003, 189: 1-10. 10.1016/S0304-3835(02)00509-8.CrossRefPubMed
4.
go back to reference Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, et al: Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol Cell. 2004, 13: 587-597. 10.1016/S1097-2765(04)00081-4.CrossRefPubMed Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, et al: Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol Cell. 2004, 13: 587-597. 10.1016/S1097-2765(04)00081-4.CrossRefPubMed
5.
go back to reference Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005, 102 (41): 14569-14664. 10.1073/pnas.0505844102.CrossRef Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005, 102 (41): 14569-14664. 10.1073/pnas.0505844102.CrossRef
6.
go back to reference Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD, Hua X: Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003, 63: 4204-4210.PubMed Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD, Hua X: Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003, 63: 4204-4210.PubMed
7.
go back to reference Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, Grompe M: Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003, 17: 2021-2035. 10.1101/gad.1103403.CrossRefPubMedPubMedCentral Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, Grompe M: Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003, 17: 2021-2035. 10.1101/gad.1103403.CrossRefPubMedPubMedCentral
8.
go back to reference Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, et al: Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999, 54: 397-438. discussion 438–399PubMed Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, et al: Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999, 54: 397-438. discussion 438–399PubMed
9.
go back to reference Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, et al: A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001, 98: 1118-1123. 10.1073/pnas.98.3.1118.CrossRefPubMedPubMedCentral Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, et al: A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001, 98: 1118-1123. 10.1073/pnas.98.3.1118.CrossRefPubMedPubMedCentral
10.
go back to reference Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX: Heterozygous Men1 mutant mice develop a range of endocrine tumors minicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003, 17: 1880-1892. 10.1210/me.2003-0154.CrossRefPubMed Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX: Heterozygous Men1 mutant mice develop a range of endocrine tumors minicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003, 17: 1880-1892. 10.1210/me.2003-0154.CrossRefPubMed
11.
go back to reference Loffler KA, Biondi CA, Gartside MG, Waring P, Stark MS, Serewko-Auret MM, Muller HK, Hayward NK, Kay GF: Broad tumour spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer. 2007, 120: 259-267. 10.1002/ijc.22288.CrossRefPubMed Loffler KA, Biondi CA, Gartside MG, Waring P, Stark MS, Serewko-Auret MM, Muller HK, Hayward NK, Kay GF: Broad tumour spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer. 2007, 120: 259-267. 10.1002/ijc.22288.CrossRefPubMed
12.
go back to reference Harding B, Lemos MC, Reed AA, Walls GV, Jeyabalan J, Bowl MR, Tateossian H, Sullivan N, Hough T, Fraser WD, et al: Multiple Endocrine Neoplasia Type 1 (MEN1) knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer. 2009, 16: 1313-1327. 10.1677/ERC-09-0082.CrossRefPubMedPubMedCentral Harding B, Lemos MC, Reed AA, Walls GV, Jeyabalan J, Bowl MR, Tateossian H, Sullivan N, Hough T, Fraser WD, et al: Multiple Endocrine Neoplasia Type 1 (MEN1) knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer. 2009, 16: 1313-1327. 10.1677/ERC-09-0082.CrossRefPubMedPubMedCentral
14.
go back to reference Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992, 356 (6366): 215-221. 10.1038/356215a0.CrossRefPubMed Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992, 356 (6366): 215-221. 10.1038/356215a0.CrossRefPubMed
15.
go back to reference Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994, 4 (1): 1-7. 10.1016/S0960-9822(00)00002-6.CrossRefPubMed Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994, 4 (1): 1-7. 10.1016/S0960-9822(00)00002-6.CrossRefPubMed
16.
go back to reference Loffler KA, Biondi CA, Gartside MG, Serewko-Auret MM, Duncan R, Tonks ID, Mould AW, Waring P, Muller HK, Kay GF, et al: Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene. 2007, 26: 4009-4017. 10.1038/sj.onc.1210163.CrossRefPubMed Loffler KA, Biondi CA, Gartside MG, Serewko-Auret MM, Duncan R, Tonks ID, Mould AW, Waring P, Muller HK, Kay GF, et al: Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene. 2007, 26: 4009-4017. 10.1038/sj.onc.1210163.CrossRefPubMed
17.
go back to reference Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994, 7 (4): 480-484. 10.1038/ng0894-480.CrossRefPubMed Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994, 7 (4): 480-484. 10.1038/ng0894-480.CrossRefPubMed
18.
go back to reference Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995, 55: 1146-1151.PubMed Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995, 55: 1146-1151.PubMed
19.
go back to reference Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001, 29: 418-425. 10.1038/ng747.CrossRefPubMed Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001, 29: 418-425. 10.1038/ng747.CrossRefPubMed
20.
go back to reference Damo LA, Snyder PW, Franklin DS: Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog. 2005, 42 (2): 109-120. 10.1002/mc.20068.CrossRefPubMed Damo LA, Snyder PW, Franklin DS: Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog. 2005, 42 (2): 109-120. 10.1002/mc.20068.CrossRefPubMed
21.
go back to reference Mould AW, Duncan R, Serewko-Auret M, Loffler KA, Biondi C, Gartside M, Kay GF, Hayward NK: Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling. Int J Cancer. 2007, 121: 776-783. 10.1002/ijc.22734.CrossRefPubMed Mould AW, Duncan R, Serewko-Auret M, Loffler KA, Biondi C, Gartside M, Kay GF, Hayward NK: Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling. Int J Cancer. 2007, 121: 776-783. 10.1002/ijc.22734.CrossRefPubMed
22.
go back to reference Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y: p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol Cell Biol. 2007, 27: 1495-1504. 10.1128/MCB.01764-06.CrossRefPubMed Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y: p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol Cell Biol. 2007, 27: 1495-1504. 10.1128/MCB.01764-06.CrossRefPubMed
23.
go back to reference Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang ZQ, Zhang CX: Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev. 2003, 120: 549-560. 10.1016/S0925-4773(03)00039-X.CrossRefPubMed Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang ZQ, Zhang CX: Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev. 2003, 120: 549-560. 10.1016/S0925-4773(03)00039-X.CrossRefPubMed
24.
go back to reference Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331 (6021): 1199-1203. 10.1126/science.1200609.CrossRefPubMedPubMedCentral Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331 (6021): 1199-1203. 10.1126/science.1200609.CrossRefPubMedPubMedCentral
25.
go back to reference Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, et al: A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development. Cancer Cell. 2010, 18 (3): 220-230. 10.1016/j.ccr.2010.07.010.CrossRefPubMedPubMedCentral Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, et al: A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development. Cancer Cell. 2010, 18 (3): 220-230. 10.1016/j.ccr.2010.07.010.CrossRefPubMedPubMedCentral
Metadata
Title
Menin and p53 have non-synergistic effects on tumorigenesis in mice
Authors
Kelly A Loffler
Arne W Mould
Paul M Waring
Nicholas K Hayward
Graham F Kay
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-252

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine